Experienced in Waldenstrom Macroglobulinemia

Dr. Mayur S. Narkhede

Hematology Oncology | Hematology | Oncology
Mercyhealth
Rockford Health Physicians
8201 E Riverside Blvd, 
Rockford, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Waldenstrom Macroglobulinemia
Mercyhealth
Rockford Health Physicians
8201 E Riverside Blvd, 
Rockford, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mayur Narkhede is a Hematologist Oncology specialist and a Hematologist in Rockford, Illinois. Dr. Narkhede is rated as an Experienced provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration. Dr. Narkhede is currently accepting new patients.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

ROCKFORD HEALTH PHYSICIANS
8201 E Riverside Blvd, Rockford, IL 61114
Other Locations
UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Siltuximab
Study Phase: Phase 2
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Biological, Drug
Study Drugs: Copanlisib Hydrochloride, Nivolumab
Study Phase: Phase 2
View 5 Less Clinical Trials

27 Total Publications

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
Journal: Blood
Published: March 06, 2025
Similar Doctors
Distinguished in Waldenstrom Macroglobulinemia
Dr. Arlene D'souza
Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Arlene D'souza
Hematology | Oncology
304 Randall Rd, 
Geneva, IL 
 (43.4 miles away)
239-692-8495
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arlene D'souza is a Hematologist and an Oncologist in Geneva, Illinois. Dr. D'souza has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Waldenstrom Macroglobulinemia, Familial Pancreatic Cancer, Multiple Myeloma, and Chronic Lymphocytic Leukemia (CLL).

Dean G. Tsarwhas
Distinguished in Waldenstrom Macroglobulinemia
Dr. Dean G. Tsarwhas
Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Dean G. Tsarwhas
Hematology | Oncology
1000 N Westmoreland Rd Level 1, Pavilion A, 
Lake Forest, IL 
 (56.1 miles away)
847-582-2134
Experience:
38+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dean Tsarwhas is a Hematologist and an Oncologist in Lake Forest, Illinois. Dr. Tsarwhas has been practicing medicine for over 38 years and is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Sezary Syndrome, Paget Disease of the Breast, Angiosarcoma, and Large-Cell Immunoblastic Lymphoma.

Distinguished in Waldenstrom Macroglobulinemia
Dr. Shannon E. O'mahar
Hematology Oncology | Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Shannon E. O'mahar
Hematology Oncology | Hematology | Oncology

Dean Health Systems Inc

1211 Fish Hatchery Rd, 
Madison, WI 
 (56.5 miles away)
608-252-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shannon O'mahar is a Hematologist Oncology specialist and a Hematologist in Madison, Wisconsin. Dr. O'mahar is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Myelodysplastic Syndrome (MDS), and Waldenstrom Macroglobulinemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Narkhede's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile